Elnara K. Ismagulova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elnara K. Ismagulova has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Gulmira Maratovna Iztleuova
West Kazakhstan Marat Ospanov Medical University
2 shared publications - Lazzat Balymbetova
West Kazakhstan Marat Ospanov Medical University
2 shared publications - Sarkit Kozhabergenovna Kozhantaeva
West Kazakhstan Marat Ospanov Medical University
2 shared publications - Yerbolat Iztleuov
West Kazakhstan Marat Ospanov Medical University
2 shared publications - Andrea Tinelli
Department of Obstetrics and Gynecology, CERICSAL (CEntro di RIcerca Clinico SALentino), “Veris delli Ponti Hospital”, Via Giuseppina Delli Ponti, 73020 Scorrano, Italy
1 shared publication - Arip Koyshybaev
«Marat Ospanov West Kazakhstan Medical University» NCJSC
1 shared publication
Latest Publications
- Open Access
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 86-95
POTENTIAL OTOTOXIC EFFECTS OF DIFFERENT GENERATIONS OF EGFR TYROSINE KINASE INHIBITORS: A LITERATURE REVIEW
Relevance: Lung cancer is one of the most frequent malignant tumors, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases. Mutations in the epidermal growth factor receptor (EGFR) gene contribute significantly to NSCLC development. EGFR is key for tumor occurrence and progression. The discovery of tyrosine kinase inhibitors (TKI) targeting EGFR has marked significant progress, offering a more rational and effective therapeutic approach. However, TKIs are not free of side effects. Evidence indicates a potential link between TKI therapy and ototoxicity. Given the chronic nature of the treatment of patients with advanced stages of the disease, even minor toxicity can significantly affect the quality of life. It is essential to inform patients about the potential risk of hearing impairment and to regularly monitor for early signs of ototoxicity, thereby optimizing long-term treatment outcomes for patients. The study aimed to review the existing data on tyrosine kinase inhibitors and their potential ototoxicity, including the main mechanisms of pathogenesis. Methods: The search utilized PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar, and ClinicalTrials.gov to identify scientific publications on ototoxicity caused by TKIs in NSCLC. The keywords “non-small cell lung cancer,” “ototoxicity,” “gefitinib,” “erlotinib,” “afatinib,” “dacomitinib,” and “osimertinib” were used for the search. Results: EGFR plays an important role in developing, maintaining, and repairing sensory and non-sensory structures of the inner ear. In neonatal models, EGFR is expressed in cochlear cells, including the cortical organ, facilitating regeneration and repair. However, in mature systems, EGFR expression decreases, primarily localized in the spiral ganglion, limiting the regenerative ability of auditory cells. By inhibiting EGFR signaling, cellular proliferation and repair mechanisms are disrupted, damaging the cochlea’s hair cells and supporting cells. Conclusion: The prevalence and main molecular mechanisms of ototoxicity caused by TKI remain poorly understood. Further research is needed to clarify dose-dependent effects, genetic predisposition, and potential protective strategies. Knowledge of this adverse effect is necessary to monitor auditory health during EGFR-TKI therapy and to study interventions that mitigate its effects on patients undergoing long-term treatment.
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 86-95
Open AccessPOTENTIAL OTOTOXIC EFFECTS OF DIFFERENT GENERATIONS OF EGFR TYROSINE KINASE INHIBITORS: A LITERATURE REVIEW
Relevance: Lung cancer is one of the most frequent malignant tumors, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases. Mutations in the epidermal growth factor receptor (EGFR) gene contribute significantly to NSCLC development. EGFR is key for tumor occurrence and progression. The discovery of tyrosine kinase inhibitors (TKI) targeting EGFR has marked significant progress, offering a more rational and effective therapeutic approach. However, TKIs are not free of side effects. Evidence indicates a potential link between TKI therapy and ototoxicity. Given the chronic nature of the treatment of patients with advanced stages of the disease, even minor toxicity can significantly affect the quality of life. It is essential to inform patients about the potential risk of hearing impairment and to regularly monitor for early signs of ototoxicity, thereby optimizing long-term treatment outcomes for patients. The study aimed to review the existing data on tyrosine kinase inhibitors and their potential ototoxicity, including the main mechanisms of pathogenesis. Methods: The search utilized PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar, and ClinicalTrials.gov to identify scientific publications on ototoxicity caused by TKIs in NSCLC. The keywords “non-small cell lung cancer,” “ototoxicity,” “gefitinib,” “erlotinib,” “afatinib,” “dacomitinib,” and “osimertinib” were used for the search. Results: EGFR plays an important role in developing, maintaining, and repairing sensory and non-sensory structures of the inner ear. In neonatal models, EGFR is expressed in cochlear cells, including the cortical organ, facilitating regeneration and repair. However, in mature systems, EGFR expression decreases, primarily localized in the spiral ganglion, limiting the regenerative ability of auditory cells. By inhibiting EGFR signaling, cellular proliferation and repair mechanisms are disrupted, damaging the cochlea’s hair cells and supporting cells. Conclusion: The prevalence and main molecular mechanisms of ototoxicity caused by TKI remain poorly understood. Further research is needed to clarify dose-dependent effects, genetic predisposition, and potential protective strategies. Knowledge of this adverse effect is necessary to monitor auditory health during EGFR-TKI therapy and to study interventions that mitigate its effects on patients undergoing long-term treatment.
- Open Access
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 86-95
POTENTIAL OTOTOXIC EFFECTS OF DIFFERENT GENERATIONS OF EGFR TYROSINE KINASE INHIBITORS: A LITERATURE REVIEW
Relevance: Lung cancer is one of the most frequent malignant tumors, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases. Mutations in the epidermal growth factor receptor (EGFR) gene contribute significantly to NSCLC development. EGFR is key for tumor occurrence and progression. The discovery of tyrosine kinase inhibitors (TKI) targeting EGFR has marked significant progress, offering a more rational and effective therapeutic approach. However, TKIs are not free of side effects. Evidence indicates a potential link between TKI therapy and ototoxicity. Given the chronic nature of the treatment of patients with advanced stages of the disease, even minor toxicity can significantly affect the quality of life. It is essential to inform patients about the potential risk of hearing impairment and to regularly monitor for early signs of ototoxicity, thereby optimizing long-term treatment outcomes for patients. The study aimed to review the existing data on tyrosine kinase inhibitors and their potential ototoxicity, including the main mechanisms of pathogenesis. Methods: The search utilized PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar, and ClinicalTrials.gov to identify scientific publications on ototoxicity caused by TKIs in NSCLC. The keywords “non-small cell lung cancer,” “ototoxicity,” “gefitinib,” “erlotinib,” “afatinib,” “dacomitinib,” and “osimertinib” were used for the search. Results: EGFR plays an important role in developing, maintaining, and repairing sensory and non-sensory structures of the inner ear. In neonatal models, EGFR is expressed in cochlear cells, including the cortical organ, facilitating regeneration and repair. However, in mature systems, EGFR expression decreases, primarily localized in the spiral ganglion, limiting the regenerative ability of auditory cells. By inhibiting EGFR signaling, cellular proliferation and repair mechanisms are disrupted, damaging the cochlea’s hair cells and supporting cells. Conclusion: The prevalence and main molecular mechanisms of ototoxicity caused by TKI remain poorly understood. Further research is needed to clarify dose-dependent effects, genetic predisposition, and potential protective strategies. Knowledge of this adverse effect is necessary to monitor auditory health during EGFR-TKI therapy and to study interventions that mitigate its effects on patients undergoing long-term treatment.
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 86-95
Open AccessPOTENTIAL OTOTOXIC EFFECTS OF DIFFERENT GENERATIONS OF EGFR TYROSINE KINASE INHIBITORS: A LITERATURE REVIEW
Relevance: Lung cancer is one of the most frequent malignant tumors, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases. Mutations in the epidermal growth factor receptor (EGFR) gene contribute significantly to NSCLC development. EGFR is key for tumor occurrence and progression. The discovery of tyrosine kinase inhibitors (TKI) targeting EGFR has marked significant progress, offering a more rational and effective therapeutic approach. However, TKIs are not free of side effects. Evidence indicates a potential link between TKI therapy and ototoxicity. Given the chronic nature of the treatment of patients with advanced stages of the disease, even minor toxicity can significantly affect the quality of life. It is essential to inform patients about the potential risk of hearing impairment and to regularly monitor for early signs of ototoxicity, thereby optimizing long-term treatment outcomes for patients. The study aimed to review the existing data on tyrosine kinase inhibitors and their potential ototoxicity, including the main mechanisms of pathogenesis. Methods: The search utilized PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar, and ClinicalTrials.gov to identify scientific publications on ototoxicity caused by TKIs in NSCLC. The keywords “non-small cell lung cancer,” “ototoxicity,” “gefitinib,” “erlotinib,” “afatinib,” “dacomitinib,” and “osimertinib” were used for the search. Results: EGFR plays an important role in developing, maintaining, and repairing sensory and non-sensory structures of the inner ear. In neonatal models, EGFR is expressed in cochlear cells, including the cortical organ, facilitating regeneration and repair. However, in mature systems, EGFR expression decreases, primarily localized in the spiral ganglion, limiting the regenerative ability of auditory cells. By inhibiting EGFR signaling, cellular proliferation and repair mechanisms are disrupted, damaging the cochlea’s hair cells and supporting cells. Conclusion: The prevalence and main molecular mechanisms of ototoxicity caused by TKI remain poorly understood. Further research is needed to clarify dose-dependent effects, genetic predisposition, and potential protective strategies. Knowledge of this adverse effect is necessary to monitor auditory health during EGFR-TKI therapy and to study interventions that mitigate its effects on patients undergoing long-term treatment.
- Open Access
- 2 June 2025
- Published by Wolters Kluwer Health in West Kazakhstan Medical Journal
- Vol. 67 (2) , 162-176
Association Mechanisms Between Periodontal Diseases and Systemic Pathology
Periodontitis is a chronic inflammatory disease caused by a dysbiotic oral microbiome and an altered immune response. It affects approximately 10% of the adult population and is one of the leading causes of tooth loss. Beyond its local consequences, periodontitis is closely associated with systemic diseases, including cardiovascular disorders, type 2 diabetes, rheumatoid arthritis, osteoporosis, chronic kidney disease, Alzheimer’s disease, pneumonia, pregnancy complications, and COVID-19. The main mechanisms underlying this relationship include chronic systemic inflammation, the spread of bacteria and their toxins through the bloodstream, and the activation of immune cells capable of exacerbating inflammation in other organs. For instance, bacterial lipopolysaccharides (LPS) and periodontopathogens such as Porphyromonas gingivalis can contribute to the development of atherosclerosis, endotoxemia, and autoimmune reactions. Further clinical studies are required to establish a causal relationship and develop effective treatment strategies. A deeper understanding of these mechanisms may facilitate the development of interdisciplinary approaches to the prevention and treatment of both periodontitis and related systemic diseases.
- 2 June 2025
- Published by Wolters Kluwer Health in West Kazakhstan Medical Journal
- Vol. 67 (2) , 162-176
Open AccessAssociation Mechanisms Between Periodontal Diseases and Systemic Pathology
Periodontitis is a chronic inflammatory disease caused by a dysbiotic oral microbiome and an altered immune response. It affects approximately 10% of the adult population and is one of the leading causes of tooth loss. Beyond its local consequences, periodontitis is closely associated with systemic diseases, including cardiovascular disorders, type 2 diabetes, rheumatoid arthritis, osteoporosis, chronic kidney disease, Alzheimer’s disease, pneumonia, pregnancy complications, and COVID-19. The main mechanisms underlying this relationship include chronic systemic inflammation, the spread of bacteria and their toxins through the bloodstream, and the activation of immune cells capable of exacerbating inflammation in other organs. For instance, bacterial lipopolysaccharides (LPS) and periodontopathogens such as Porphyromonas gingivalis can contribute to the development of atherosclerosis, endotoxemia, and autoimmune reactions. Further clinical studies are required to establish a causal relationship and develop effective treatment strategies. A deeper understanding of these mechanisms may facilitate the development of interdisciplinary approaches to the prevention and treatment of both periodontitis and related systemic diseases.
- 10 June 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (18) , 2073-2086
Human Papillomavirus Selected Properties and Related Cervical Cancer Prevention Issues
High-risk human papillomavirus strains are widely known to be the causative agents responsible for cervical cancer development. Aggregated damage caused by papillomaviruses solely is estimated in at least 5% of all malignancies of the human body and 16% in cancers that affect the female genital area. Enhanced understanding of the complex issue on how the high extent of carcinogenicity is eventually formed due to the infection by the Papoviridae family would contribute to enhancing current prevention strategies not only towards cervical cancer, but also other HPV associated cancers. This review article is aimed at presenting the key points in two directions: the current cervical cancer prevention and related aspects of HPV behavior. Virtually all applied technologies related to HPV diagnostics and screening programs, such as HPV tests, colposcopy-based tests (VIA/VILI), conventional and liquid-based cytology, currently available are presented. Issues of availability, advantages, and drawbacks of the screening programs, as well as vaccination strategies, are also reviewed in the article based on the analyzed sources. The current point of view regarding HPV is discussed with emphasis on the most problematic aspect of the HPV family concerning the observed increasing number of highly carcinogenic types. Present trends in HPV infection diagnostics throughout the human fluids and tissues are also reported, including the latest novelties in this field, such as HPV assay/self-sample device combinations. Besides, a brief outline of the related prevention issues in Kazakhstan, the leading country of Central Asia, is presented. Kazakhstan, as one of the post-soviet middle-income countries, may serve as an example of the current situation in those terrains, concerning the implementation of globally accepted cervical cancer prevention strategies. Along with positive achievements, such as the development of a nationwide screening program, a range of drawbacks is also analyzed and discussed.
- 10 June 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (18) , 2073-2086
Human Papillomavirus Selected Properties and Related Cervical Cancer Prevention Issues
High-risk human papillomavirus strains are widely known to be the causative agents responsible for cervical cancer development. Aggregated damage caused by papillomaviruses solely is estimated in at least 5% of all malignancies of the human body and 16% in cancers that affect the female genital area. Enhanced understanding of the complex issue on how the high extent of carcinogenicity is eventually formed due to the infection by the Papoviridae family would contribute to enhancing current prevention strategies not only towards cervical cancer, but also other HPV associated cancers. This review article is aimed at presenting the key points in two directions: the current cervical cancer prevention and related aspects of HPV behavior. Virtually all applied technologies related to HPV diagnostics and screening programs, such as HPV tests, colposcopy-based tests (VIA/VILI), conventional and liquid-based cytology, currently available are presented. Issues of availability, advantages, and drawbacks of the screening programs, as well as vaccination strategies, are also reviewed in the article based on the analyzed sources. The current point of view regarding HPV is discussed with emphasis on the most problematic aspect of the HPV family concerning the observed increasing number of highly carcinogenic types. Present trends in HPV infection diagnostics throughout the human fluids and tissues are also reported, including the latest novelties in this field, such as HPV assay/self-sample device combinations. Besides, a brief outline of the related prevention issues in Kazakhstan, the leading country of Central Asia, is presented. Kazakhstan, as one of the post-soviet middle-income countries, may serve as an example of the current situation in those terrains, concerning the implementation of globally accepted cervical cancer prevention strategies. Along with positive achievements, such as the development of a nationwide screening program, a range of drawbacks is also analyzed and discussed.